Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvocidib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 14/20 | 1.00 |
| ▸ | CDK4 known ✓ | P11802 | 12/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 11/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 10/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 3/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 11/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 9/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 9/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 8/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 6/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 6/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvocidib SCHEMBL5868074 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29351027 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29577824 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL12445809 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29388553 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL8214028 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3651 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL16927354 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Flavopyridol SCHEMBL22580715 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL28199338 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26103 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260102468-A1 | COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY | UNIV TEXAS (US) | 2026-04-16 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| US-20260076952-A1 | Agent for Treatment of Neutropenia | UNIV TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2026-03-19 | — | — | US | claimed |
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-10 | — | — | US | claimed |
| US-20260053750-A1 | INHALABLE COMPOSITIONS OF CDK9 INHIBITORS | OWEN MATTHEW (US) | 2026-02-26 | — | — | US | claimed |
| EP-4683632-A1 | A CYCLIN-DEPENDENT KINASE 2/4/9 INHIBITOR FOR THE TREATMENT OF NEUTROPENIA | Eberhard Karls Universität Tübingen, Medizinische Fakultät (DE) | 2026-01-28 | — | — | EP | claimed |
| US-20260014140-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS INC (US) | 2026-01-15 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| WO-2000044362-A2 | THE USE OF 4-H-1-BENZOPYRAN-4-ONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AVENTIS PHARMACEUTICALS INC. (US) | 2000-08-03 | — | — | WO | claimed |
| US-6087366-A | Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2000-07-11 | — | — | US | claimed |
| WO-2000029427-A2 | ANTENNAPEDIA HOMEODOMAIN HELIX 3 DERIVED TRANSLOCATION VECTORS | CYCLACEL LIMITED (GB) | 2000-05-25 | — | — | WO | claimed |
| WO-2000024885-A2 | p53 MORPHOLINO-BASED ANTISENSE | AVI BIOPHARMA, INC. (US) | 2000-05-04 | — | — | WO | claimed |
| WO-2000001417-A1 | DELIVERY SYSTEM | CYCLACEL LIMITED (GB) | 2000-01-13 | — | — | WO | claimed |
| WO-1999032660-A9 | EXPLOITING GENOMICS IN THE SEARCH FOR NEW DRUGS | AFFYMETRIX INC (US) | 1999-09-23 | — | — | WO | claimed |
| WO-1999032660-A1 | EXPLOITING GENOMICS IN THE SEARCH FOR NEW DRUGS | AFFYMETRIX (US) | 1999-07-01 | — | — | WO | claimed |
| EP-0919244-A2 | Combinations for the treatment of tumours | Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften (DE) | 1999-06-02 | — | — | EP | claimed |
| EP-0888458-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | Sloan-Kettering Institute For Cancer Research (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997030174-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-08-21 | — | — | WO | claimed |